Search - tctmd.com

Displaying 501 - 520 of 664

Sort: Relevancy | Date

News Daily News

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

L.A. McKeown

February 26, 2015

News Daily News

XAMI at 3 Years: Rates of Very Late Stent Thrombosis Similarly Low for EES, SES in Acute MI Patients

L.A. McKeown

January 29, 2015

News Daily News

DES With Biodegradable Polymer Safe, Durable Through 5 Years

L.A. McKeown

January 28, 2015

News Features

Drug-Coated Balloon Approvals Mark ‘Sea Change’ for Treatment of PAD

L.A. McKeown

January 28, 2015

News Daily News

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Salynn Boyles

December 15, 2014

News Daily News

Manifestation of In-Stent Restenosis More Tightly Linked to Patient Than Device Factors

Salynn Boyles

December 11, 2014

News Conference News AHA 2014

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

November 18, 2014

News Daily News

OCT Study Suggests Plaque ‘Capping’ Safer With BRS Than BMS

November 06, 2014

News Conference News TCT 2014

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

September 19, 2014

News Conference News TCT 2014

Long-term Outcomes Worse for Patients with Coronary Artery Aneurysm After DES Implantation

Yael L. Maxwell

September 19, 2014

Presentation TCT 2014

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Kenya Brothers

September 16, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

Presentation TCT 2014

Future BRS Directions: New Platforms and Devices to Address Current Technical Limitations

Presenter: Alexandre Abizaid, Helio R Figueira, Jamil Abdalla Saad

September 13, 2014

Presentation TCT 2014

Bare Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Emmanouil S. Brilakis, J. Dawn Abbott

September 13, 2014

News Conference News TCT 2014

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

September 13, 2014

News Conference News TCT 2014

COMPARE II: BES, EES Show Similar Outcomes at Three Years

September 13, 2014

News Conference News ESC 2014

PROTECT: ZES Sustain Lead Over SES at 5 Years

Caitlin E. Cox

September 03, 2014

News Daily News

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

L.A. McKeown

September 02, 2014

News Conference News ESC 2014

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Yael L. Maxwell

September 01, 2014

News Conference News ESC 2014

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Todd Neale

August 30, 2014

Advertisement

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

XAMI at 3 Years: Rates of Very Late Stent Thrombosis Similarly Low for EES, SES in Acute MI Patients

DES With Biodegradable Polymer Safe, Durable Through 5 Years

Drug-Coated Balloon Approvals Mark ‘Sea Change’ for Treatment of PAD

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Manifestation of In-Stent Restenosis More Tightly Linked to Patient Than Device Factors

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

OCT Study Suggests Plaque ‘Capping’ Safer With BRS Than BMS

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

Long-term Outcomes Worse for Patients with Coronary Artery Aneurysm After DES Implantation

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Future BRS Directions: New Platforms and Devices to Address Current Technical Limitations

Bare Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

COMPARE II: BES, EES Show Similar Outcomes at Three Years

PROTECT: ZES Sustain Lead Over SES at 5 Years

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content